3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
6
Stomach Neoplasms
3
Pain, Postoperative
3
Breast Neoplasms
3
Neurotoxicity Syndromes
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Multiple Endocrine Neoplasia Type 1
2
Lung Neoplasms
2
Delirium
2
Colonic Neoplasms
2
Warts
1
Thoracic Neoplasms
1
Spondylitis, Ankylosing
1
Spinal Cord Neoplasms
1
Skin Diseases
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Pituitary Neoplasms
1
Pituitary Diseases
1
Peripheral Nervous System Diseases
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Meningioma
1
Lymphoma, Follicular
1
Low Back Pain
1
Fallopian Tube Neoplasms
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Sodium Chloride
×
Clear all
NCT05250791
2023-06-09
FLICOR
Imperial College London
Phase NA
Unknown
50 enrolled